Merck Corporate Integrity Agreement

Merck has also entered into a new Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the U.S. Department of Health. This agreement replaces Merck`s current CIA and builds on the company`s existing global compliance program. Merck`s compliance program includes specific guidelines and procedures governing the company`s management of healthcare professionals and aims to prevent, detect and remedy possible violations of company policies or laws. WHITEHOUSE STATION, N.J., November 22, 2011 – Merck (NYSE: MRK), outside the United States and Canada as MSD, announced that it has reached an agreement with federal and state authorities on a previously published investigation into Vioxx. Merck voluntarily withdrew Vioxx from the market in September 2004. The company had already recorded a charge of $950 million in October 2010 pending the current agreements. Merck is now a global healthcare leader committed to making the world a good place. Merck is known as MSD outside of the United States and Canada. Through our medicines, vaccines, biological therapies, consumer and animal health products, we work with our customers and work in more than 140 countries to provide innovative health solutions. We also demonstrate our commitment to increasing access to health care through broad guidelines, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

As part of the appeal agreement, the United States acknowledged that there was no basis for establishing the involvement of high-level management in the breach. The government also acknowledged Merck`s full cooperation in the investigation. The new self-monitoring component allows us to monitor the effectiveness of our compliance program within a company. Specific risk reduction statements shall be made available to the Director General of the legal person or the Director General of a division within the scope, which must be certified at the level of an agreement. “We believe Merck acted responsibly and in good faith with respect to the conduct at issue in these civil settlement agreements, including Vioxx`s safety profile activities,” said Bruce N. Kuhlik, Executive Vice President and General Counsel of Merck. As part of the transaction, Merck has also agreed to enter into a comprehensive agreement with the Office of Inspector General of the Department of Health and Human Services (HHS-OIG), which will strengthen the system of audits and monitoring procedures imposed on the company. . . .